Table 4.
China/this study | Turkey [16] | Korea [22] | US [21] | China [15] | Mexico [34] | Korea [25] | India [26] | Japan [26] | Thailand [13] | |
---|---|---|---|---|---|---|---|---|---|---|
n | 411 | 248 | 204d | 126e | 125 | 110 | 108 | 102 | 79 | 63 |
Disease durations (months) | 21.0 (6.0, 60.0)a | 34.2 (0, 240)b | ND | 13.3 (6.1, 35.5)a | 19 (0.5, 160)b | ND | 13.9 ± 10.1 (1, 60)b | ND | 24.3 ± 11.5c | ND |
Type I (%) | 22.1 | 32 | 11.1 | 20 | 40 | 19 | 36.1 | 6.9 | 24.1 | 0 |
Type IIa (%) | 3.9 | 6.9 | 8.6 | 6 | 4.8 | 3 | 2.8 | 1 | 11.4 | 0 |
Type IIb (%) | 3.9 | 3.2 | 14.1 | 7 | 1.6 | 4 | 4.6 | 5.9 | 10.1 | 11.1 |
Type III (%) | 2.9 | 3.2 | 4.0 | 5 | 2.4 | 4 | 7.4 | 2.9 | 0 | 3.2 |
Type IV (%) | 6.3 | 3.7 | 7.6 | 5 | 20.8 | 2 | 15.7 | 28.4 | 1.3 | 19 |
Type V (%) | 60.8 | 51 | 54.5 | 57 | 30.4 | 69 | 33.3 | 54.9 | 53.2 | 66.7 |
aMedian (Q1,Q3)
bMedian (range)
cYears
d198 patients had undergone angiographic evaluation
e100 patients had undergone angiographic evaluation
ND no data